New Technologies for Cell Therapy Manufacturing with Invetech

26 August 2022
Cell Therapy
Gene Therapy
David Hodl, Head of Business Development at Invetech, joined us to discuss the future of cell therapy manufacturing, ahead of Invetech’s appearance at Phacilitate’s Advanced Therapies Europe, Aug 31st –Sept 1st, and Invetech’s Michelle Duquette’s presentation of clinical data of its newly launched Korus platform, at the event (Sep 1st, 1:30 pm).

In this short interview, David Hodl describes the different solutions and systems being adopted in order to optimize cell-based therapy manufacturing and take development from the lab to a commercial scale.

Cell therapy manufacturers face many challenges when looking to streamline and scale processes in a safe, efficacious, and cost-effective manner. David notes that tackling these challenges involves, considering the variability of incoming starting materials, facing issues surrounding affordability and patient accessibility, and, recognizing the importance of standardization.

You can join Invetech’s Michelle Duquette at Advanced Therapies Europe in the session ‘THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES’, Thursday the 1st of August at 1:30 pm, to hear more about Korus.

Find out more about Invetech’s Korus Technology here.

This interview has been produced in partnership with Invetech.

How are you enjoying this interview? Let us know your thoughts, here >>

While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to